# OP-3136 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/op-3136

> The next catalyst for OP-3136, sponsored by Olema Oncology, Inc. (OLMA), is its topline data readout, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, year only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for OP-3136?

The next catalyst for OP-3136, sponsored by Olema Oncology, Inc. (OLMA), is its topline data readout, 2027. SEC prospectus (424B): "We expect initial clinical results from the OP-3136 Phase 1 study in mid-2026, potential additional data readout in 2027, and potential initiation of a Phase 3 clinical trial in 2028." [Calendar and source filings](https://sec-api.dev/pdufa/op-3136)

Source: SEC prospectus (424B), accession 0001193125-25-288287, https://www.sec.gov/Archives/edgar/data/1750284/000119312525288287/d846460d424b5.htm (retrieved 2026-11-12). Last confirmed 2025-11-19. Cite: https://sec-api.dev/pdufa/op-3136#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | OP-3136 |
| Codes | OP-3136 |
| Sponsor | Olema Oncology, Inc. (OLMA) https://sec-api.dev/companies/olma/catalysts |
| Indications | er+/her2- metastatic breast cancer and other cancers |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Jan 2024: trial start

- Status: completed. Date confidence: month. Stage: 1. Indication: ER+/HER2- metastatic breast cancer and other cancers.
- First seen 2025-03-18, last confirmed 2026-03-16.
- SEC Form 10-K (accession 0001193125-26-107169): "In January 2024, we nominated a development candidate for this program, OP-3136 and in late 2024, the IND application for OP-3136 was cleared by the FDA and we initiated a Phase 1 clinical trial evaluating OP-3136 in patients with ER+/HER2- metastatic breast cancer and other cancers." https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm
- SEC Form 10-K (accession 0000950170-25-041204): "In January 2024, we nominated a development candidate for this program, OP-3136 and in late 2024, the IND application for OP-3136 was cleared by the FDA and we initiated a Phase 1 clinical trial evaluating OP-3136 in patients with ER+/HER2- metastatic breast cancer and other cancers." https://www.sec.gov/Archives/edgar/data/1750284/000095017025041204/olma-20241231.htm

### early 2025: trial start

- Status: scheduled. Date confidence: half. Stage: 1.
- First seen 2024-11-12, last confirmed 2024-12-10.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-125384): "Olema has successfully completed IND-enabling studies in support of a potential Investigational New Drug (IND) application with the FDA and expects to initiate Phase 1 clinical trials for OP-3136 in early 2025." https://www.sec.gov/Archives/edgar/data/1750284/000095017024125384/olma-ex99_1.htm
- SEC Form 8-K (accession 0000950170-24-134759): "The Company expects to initiate the Phase 1 clinical trial in early 2025." https://www.sec.gov/Archives/edgar/data/1750284/000095017024134759/olma-20241209.htm

### 2026: topline data readout

- Status: scheduled. Date confidence: year.
- First seen 2026-03-16, last confirmed 2026-03-16.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-107154): "With initial clinical results from OP-3136 anticipated in Q22026, top-line data from OPERA-01 expected in the fall of this year, and commercial launch preparations underway for a potential approval in late 2027, we are entering an exciting chapter in Olema's history." https://www.sec.gov/Archives/edgar/data/1750284/000119312526107154/olma-ex99_1.htm

### May 30, 2026: interim data readout

- Status: scheduled. Date confidence: exact. Stage: 1.
- First seen 2026-03-16, last confirmed 2026-05-26.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-237832): "As previously announced, Olema will present initial clinical data from the Phase 1 study of OP-3136 in a poster presentation on May 30, 2026 at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois." https://www.sec.gov/Archives/edgar/data/1750284/000119312526237832/olma-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-107154): "Continued enrollment in the Phase 1 clinical study of OP-3136 in breast cancer and other solid tumors, with initial clinical data expected in Q2 2026" https://www.sec.gov/Archives/edgar/data/1750284/000119312526107154/olma-ex99_1.htm
- SEC Form 10-K (accession 0001193125-26-107169): "The Phase 1 clinical trial is enrolling patients, and we expect to present initial clinical data from this program in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm

### 2027: topline data readout

- Status: scheduled. Date confidence: year. Stage: 1.
- First seen 2025-08-11, last confirmed 2025-11-19.
- SEC prospectus (424B) (accession 0001193125-25-288287): "We expect initial clinical results from the OP-3136 Phase 1 study in mid-2026, potential additional data readout in 2027, and potential initiation of a Phase 3 clinical trial in 2028." https://www.sec.gov/Archives/edgar/data/1750284/000119312525288287/d846460d424b5.htm
- SEC prospectus (424B) (accession 0001193125-25-286466): "We expect initial clinical results from the OP-3136 Phase 1 study in mid-2026, potential additional data readout in 2027, and potential initiation of a Phase 3 clinical trial in 2028." https://www.sec.gov/Archives/edgar/data/1750284/000119312525286466/d846460d424b5.htm
- SEC Form 10-Q (accession 0001193125-25-273236): "We expect initial clinical results from the OP-3136 Phase 1 study in mid-2026, potential additional data readout in 2027, and potential initiation of a Phase 3 clinical trial in 2028." https://www.sec.gov/Archives/edgar/data/1750284/000119312525273236/olma-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-106565): "We expect initial clinical results from the OP-3136 Phase 1 study in 2026, potential additional data readout in 2027, and potential initiation of a Phase 3 clinical trial in 2028." https://www.sec.gov/Archives/edgar/data/1750284/000095017025106565/olma-20250630.htm

### 2028: trial start

- Status: scheduled. Date confidence: year. Stage: 3.
- First seen 2025-08-11, last confirmed 2025-11-19.
- SEC prospectus (424B) (accession 0001193125-25-288287): "We expect initial clinical results from the OP-3136 Phase 1 study in mid-2026, potential additional data readout in 2027, and potential initiation of a Phase 3 clinical trial in 2028." https://www.sec.gov/Archives/edgar/data/1750284/000119312525288287/d846460d424b5.htm
- SEC prospectus (424B) (accession 0001193125-25-286466): "We expect initial clinical results from the OP-3136 Phase 1 study in mid-2026, potential additional data readout in 2027, and potential initiation of a Phase 3 clinical trial in 2028." https://www.sec.gov/Archives/edgar/data/1750284/000119312525286466/d846460d424b5.htm
- SEC Form 10-Q (accession 0001193125-25-273236): "We expect initial clinical results from the OP-3136 Phase 1 study in mid-2026, potential additional data readout in 2027, and potential initiation of a Phase 3 clinical trial in 2028." https://www.sec.gov/Archives/edgar/data/1750284/000119312525273236/olma-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-106565): "We expect initial clinical results from the OP-3136 Phase 1 study in 2026, potential additional data readout in 2027, and potential initiation of a Phase 3 clinical trial in 2028." https://www.sec.gov/Archives/edgar/data/1750284/000095017025106565/olma-20250630.htm

Calendar months: [May 2026](https://sec-api.dev/fda-calendar/2026-05)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/op-3136.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "OP-3136 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/op-3136

```bibtex
@misc{secapidev_pdufa_op_3136_20261116,
  title        = {OP-3136 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/op-3136}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_op_3136_20261116","title":"OP-3136 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/op-3136","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
